Purine P1 receptor-dependent immunostimulatory effects of antiviral acyclic analogues of adenine and 2,6-diaminopurine.

[1]  M. Denison,et al.  Innovations in Antiviral Development and the Detection of Virus Infections , 2012, Advances in Experimental Medicine and Biology.

[2]  A. Holý,et al.  Involvement of adenosine A1 receptors in upregulation of nitric oxide by acyclic nucleotide analogues. , 2004, European journal of pharmacology.

[3]  J. Geiger,et al.  Activation of adenosine receptors inhibits tumor necrosis factor-alpha release by decreasing TNF-alpha mRNA stability and p38 activity. , 2004, European journal of pharmacology.

[4]  A. Holý.  Phosphonomethoxyalkyl analogs of nucleotides. , 2003, Current pharmaceutical design.

[5]  A. Holý,et al.  Immunobiological activity of N-[2-(phosphonomethoxy)alkyl] derivatives of N6-substituted adenines, and 2,6-diaminopurines. , 2003, European journal of pharmacology.

[6]  E. De Clercq,et al.  Antiretrovirus Activity of a Novel Class of Acyclic Pyrimidine Nucleoside Phosphonates , 2002, Antimicrobial Agents and Chemotherapy.

[7]  I. Votruba,et al.  Synthesis and Cytostatic Activity of N‐[2‐(Phosphonomethoxy)alkyl] Derivatives of N6‐Substituted Adenines, 2,6‐Diaminopurines and Related Compounds. , 2002 .

[8]  E. De Clercq,et al.  6-[2-(Phosphonomethoxy)alkoxy]pyrimidines with antiviral activity. , 2002, Journal of medicinal chemistry.

[9]  R. McIntyre,et al.  Suppression of tumor necrosis factor alpha production by cAMP in human monocytes: dissociation with mRNA level and independent of interleukin-10. , 2001, The Journal of surgical research.

[10]  George Kollias,et al.  Interleukin‐10 targets p38 MAPK to modulate ARE‐dependent TNF mRNA translation and limit intestinal pathology , 2001, The EMBO journal.

[11]  I. Votruba,et al.  Synthesis and cytostatic activity of n-[2-(phosphonomethoxy)alkyl] derivatives of N6-substituted adenines, 2,6-diaminopurines and related compounds , 2001 .

[12]  A. Holý,et al.  Macrophage activation by antiviral acyclic nucleoside phosphonates in dependence on priming immune stimuli. , 2000, International journal of immunopharmacology.

[13]  G. Chrousos,et al.  Ligand-Activation of the Adenosine A2a Receptors Inhibits IL-12 Production by Human Monocytes , 2000, The Journal of Immunology.

[14]  W. Watson,et al.  S-adenosylmethionine attenuates the lipopolysaccharide-induced expression of the gene for tumour necrosis factor alpha. , 1999, The Biochemical journal.

[15]  E. Vizi,et al.  An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. , 1998, European journal of pharmacology.

[16]  T. Shanley,et al.  Suppression of macrophage inflammatory protein (MIP)‐1α production and collagen‐induced arthritis by adenosine receptor agonists , 1998, British journal of pharmacology.

[17]  C. Szabó,et al.  Adenosine receptor agonists inhibit Macrophage Inflammatory Protein (MIP)-1α production in immunostimulated macrophages , 1998 .

[18]  A. Judd,et al.  Adenosine increases interleukin 6 release and decreases tumour necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages. , 1997, Cytokine.

[19]  E. Vizi,et al.  Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. , 1996, Journal of immunology.

[20]  L. Schook,et al.  Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. , 1996, European journal of pharmacology.

[21]  I. Votruba,et al.  Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon. , 1996, Molecular pharmacology.

[22]  O. Moine,et al.  Adenosine enhances IL-10 secretion by human monocytes. , 1996, Journal of immunology.

[23]  G. Firestein,et al.  Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. , 1996, Journal of immunology.

[24]  W. Buurman,et al.  Differential regulatory effects of adenosine on cytokine release by activated human monocytes. , 1994, Journal of immunology.

[25]  J. Lemasters,et al.  Suppression of lipopolysaccharide‐stimulated release of tumor necrosis factor by adenosine: Evidence for A2 receptors on rat kupffer cells , 1994, Hepatology.

[26]  E. De Clercq,et al.  Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Vlach,et al.  Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. , 1990, Antiviral research.

[28]  I. Votruba,et al.  Inhibition of avian myeloblastosis virus reverse transcriptase by diphosphates of acyclic phosphonylmethyl nucleotide analogues. , 1990, Antiviral research.

[29]  S. Crowe.  New reverse transcriptase inhibitors. , 1999, Advances in experimental medicine and biology.

[30]  L. Chauvelot‐Moachon,et al.  Inhibition of human monocyte TNF production by adenosine receptor agonists. , 1993, Life sciences.

[31]  H. Ho,et al.  Cellular metabolism and enzymatic phosphorylation of 9-(2-phosphonylmethoxyethyl) guanine (PMEG), a potent antiviral agent. , 1992, Advances in experimental medicine and biology.